HC Wainwright keeps Palvella Therapeutics at "buy" with $246 price target
HC Wainwright & Co. maintained its "buy" rating and $246 price target for Palvella Therapeutics. That target implies 68.8% upside from the November 19 close of $145.77. The four most recent analyst notes on the company over the past 30 days set price targets between $228 and $243.
In 25 seconds
- HC Wainwright & Co. reiterates its "buy" rating for Palvella Therapeutics.
- The price target remains at $246 per share.
- The target implies 68.8% upside from the November 19 close of $145.77.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.